Scholarlink

<p>The study investigated whether asialoglycoprotein receptor 1 (Asgr1) can serve as a biomarker for polycystic ovary syndrome (PCOS). It is known that Asgr1 loss-of-function variants are associated with lower cholesterol levels and reduced cardiovascular disease risk, but its role as a PCOS biomarker was unclear. In this clinical translational study involving 60 women undergoing IVF at the Assisted Reproductive Center of Northwest Women’s and Children’s Hospital in Xi’an, China (including controls and PCOS patients), Asgr1 levels in granulosa cells were significantly higher in PCOS women compared to controls (1.2 [0.6–1.8] vs. 2.0 [1.3–2.9], <i>p</i> &lt; 0.001). The receiver operating characteristics curve showed Asgr1 had a predictive value of 0.747 (95%CI: 0.623–0.870) for PCOS. Among individuals with a BMI of 18.5–25 treated with a gonadotropin-releasing hormone (GnRH) agonist protocol, Asgr1 levels positively correlated with gonadotropin dosage. While this is the first study to link Asgr1 to PCOS, its sample size was limited, requiring larger cohorts to confirm Asgr1’s predictive accuracy for PCOS. The findings provide a potential new biomarker for PCOS diagnosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Increased Asialoglycoprotein Receptor 1 Level in Granulosa Cell as a Potential Biomarker for Polycystic Ovary Syndrome

  • 期刊论文

  • 发表日期：

    2026年1月5日

查看全文
  • Xitong Liu,
  • Rongxia Xie,
  • Yang Cai,
  • Hui Lan,
  • Jing Mu,
  • Chen Zhang,
  • Bo Li

摘要

The study investigated whether asialoglycoprotein receptor 1 (Asgr1) can serve as a biomarker for polycystic ovary syndrome (PCOS). It is known that Asgr1 loss-of-function variants are associated with lower cholesterol levels and reduced cardiovascular disease risk, but its role as a PCOS biomarker was unclear. In this clinical translational study involving 60 women undergoing IVF at the Assisted Reproductive Center of Northwest Women’s and Children’s Hospital in Xi’an, China (including controls and PCOS patients), Asgr1 levels in granulosa cells were significantly higher in PCOS women compared to controls (1.2 [0.6–1.8] vs. 2.0 [1.3–2.9], p < 0.001). The receiver operating characteristics curve showed Asgr1 had a predictive value of 0.747 (95%CI: 0.623–0.870) for PCOS. Among individuals with a BMI of 18.5–25 treated with a gonadotropin-releasing hormone (GnRH) agonist protocol, Asgr1 levels positively correlated with gonadotropin dosage. While this is the first study to link Asgr1 to PCOS, its sample size was limited, requiring larger cohorts to confirm Asgr1’s predictive accuracy for PCOS. The findings provide a potential new biomarker for PCOS diagnosis.